Vizgen laid off an undisclosed number of employees as part of a strategic reorganization, according to the company’s statement and reports from affected workers. The spokesperson said the firm is investing in “key growth areas,” including neuro discovery in academia and biopharma, while leveraging partners for manufacturing capabilities. The restructuring impacted both R&D and commercial functions, with employees describing job cuts across lab science, computational roles, and sales. Vizgen’s layoffs follow a January $48 million funding round intended to expand commercial capabilities and growth pipeline execution. The move highlights the cash-management pressure on spatial biology companies as they balance instrument sales, workflow adoption, and the buildout of applications teams.